Table 2.

Time course of adverse events (AEs) utilizing multiple increasing doses of custirsen (group B only)

	Day 2	Day 4	Day 6	Day 8
n (%)	320 mg(n =12)	480 mg(n =12)	640 mg(n =11)	640 mg(n =11)
Subjects with at least one AE*	5 (42)	6 (50)	4 (36)	11 (100)
Constitutional AEs
Myalgia	4 (33)	4 (33)	0	0
Chills	2 (17)	2 (17)	0	0
Fatigue	1 (8)	0	0	0
Pyrexia	1 (8)	2 (17)	0	0
Dizziness	1 (8)	0	0	0
Headache	1 (8)	3 (25)	1 (9)	0
Flushing	0	1 (8)	0	0
Other AEs
Activated partial thromboplastin time prolonged	0	0	0	11 (100)
Alanine aminotransferase increased	0	0	3 (27)	0
Aspartate aminotransferase increased	0	0	1 (9)	0
Gamma glutamyl transferase increased	0	0	1 (9)	0
Muscle spasms	0	1 (8)	0	0
Eye pain	0	1 (8)	0	0
Blurred vision	1 (8)	0	0	0

^*Events with onset on or after first dose of study drug (on-study events). All events listed according to MedDRA Version 15.0 preferred term.